<DOC>
	<DOC>NCT01552057</DOC>
	<brief_summary>The purpose of the study is to assess the effectiveness and safety of duloxetine in participants with fibromyalgia.</brief_summary>
	<brief_title>A Study of Duloxetine in Fibromyalgia</brief_title>
	<detailed_description />
	<mesh_term>Fibromyalgia</mesh_term>
	<mesh_term>Myofascial Pain Syndromes</mesh_term>
	<mesh_term>Duloxetine Hydrochloride</mesh_term>
	<criteria>Participants fulfilling the following criteria in the American College of Rheumatology 1990 Criteria for the Classification of Fibromyalgia Participants with pain rated severity 4 or over by Brief Pain Inventory (BPI) average pain severity item (Question 3) Participants with serious cardiovascular, hepatic, renal, respiratory, or hematological disease, or clinically significant laboratory or electrocardiogram abnormality which indicate a serious medical problem or require significant intervention in the judgment of the investigators Participants with alanine aminotransferase/aspartate aminotransferase of not less than 100 international units per liter (IU/L) or total bilirubin of not less than 1.6 milligrams per deciliter (mg/dL) Participants with serum creatinine level of not less than 2.0 mg/dL, participant who has undergone kidney transplantation or hemodialysis Participants with pain difficult to discriminate from pain associated with fibromyalgia or disease which disturbs the assessment Participants with treatmentrefractory fibromyalgia Participants with thyroidal dysfunction, excluding those assessed by the investigator that the disorder is controlled as appropriate by 3month or longer drug therapy Participants with present or past history of rheumatoid arthritis, inflammatory arthritis, infectious arthritis, or auto immune disease rather than thyroid deficiency Participants with an axis I condition according to Diagnostic and Statistical Manual of Mental Disorders Fourth Edition (DSMIV), currently or within the past year, except for major depressive disorders Participants with a lifetime diagnosis of bipolar disorder or schizoaffective disorder; or any other disorder with psychotic symptoms based on the clinical opinion of the investigator Participants with personality disorder or mental retardation Participants with uncontrolled angle closure glaucoma Participants with present or past history of uncontrolled seizures or convulsion disorders Participants with suicidal ideation within past 6 months, with suicidal attempt within past 1 year Participants answering "yes" to any of the questions about active suicidal ideation/intent/behaviors occurring within the past 6 months (Columbia Suicide Severity Rating Scale, Suicide Ideation section Questions 4 and 5; Suicidal Behavior section) Participants with past history of multiple episodes of drug allergy Female participants who are pregnant, lactating, or who want to get pregnant during the study period. Male participants who want his partner to get pregnant Females of childbearing potential who can't agree to utilize medically. acceptable and reliable means of birth control during the study and for 1 month following the last dose of the study Participants with a history of alcohol or any psychoactive substance abuse or dependence (including alcohol, but excluding nicotine and caffeine) within the past 1 year Participants who have a positive urine drug screen for any substance of abuse (phencyclidine, cocaine, antihypnotic agent, or cannabis) Participants previously treated with duloxetine</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>74 Years</maximum_age>
	<verification_date>January 2015</verification_date>
</DOC>